---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012303"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:08:23.904735+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reviva targets brilaroxazine patent extension to 2046, plans API switch in RECOVER-2 trial

## Summary
- Filed composition of matter patent on new brilaroxazine form; pursuing accelerated review to extend exclusivity potentially through 2046.
- Preparing to seek FDA alignment to switch API and formulation in RECOVER-2; feedback expected mid-2026.
- RECOVER-2 trial activities start Q2 2026, patient enrollment Q3 2026, completion expected Q4 2027.
- Closed $10M financing on March 20, 2026; pro forma cash ~$23M, expected to fund operations into Q1 2027.
- Evaluating strategic alternatives to maximize brilaroxazine value; recent reverse stock split and financing were difficult but necessary.

## SEC filing metadata
- accession: 0001437749-26-012303
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/0001437749-26-012303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/rvph20260414_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012303
- JSON: https://secwatch.observer/filing/0001437749-26-012303.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.